Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132711 | 0.82 | FDPS (0.44) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL12076054 | 0.81 | FDPS (0.48) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL7954088 | 0.76 | FDPS (0.48) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL24026519 | 0.73 | FDPS (0.50) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL4097085 | 0.72 | FDPS (0.55) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL3846262 | 0.68 | — | — | |
| SCHEMBL16639272 | 0.67 | LMNA (0.43) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL2384958 | 0.66 | LMNA (0.56) | FDPSGRM4LMNAPDE3AADRB3 | |
| SCHEMBL10640273 | 0.65 | — | — | |
| SCHEMBL5355267 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242893-A1 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2022-08-04 | — | — | US | disclosed |
| US-9650414-B1 | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242893-A1 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | AADAC, DNPEP, NAALAD2 | FDPS 769/4885GRM4 2329/4885LMNA 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.